The Healthcare practice at MarketsandMarkets is pleased to announce its Analyst Briefing Presentation on U.S. Biopharmaceutical Market - Trends, Forecast, Competition & Strategic Analysis (2009 - 2016) to be held on 14 Dec 2010.
The U.S. biopharmaceuticals market is expected to increase to $144 billion by 2016. The growth is expected as a result of the launch of new products, approval of new indications for existing therapies and drugs, and increase in population aged 65 years and above. From 2009 to 2016 the U.S. market revenues are forecasted to grow at a compound annual growth rate (CAGR) of 11.2%.
This research report analyzes the U.S. biopharmaceuticals market and its growth factors, with special emphasis on the top companies in the field and their product pipeline. While it looks at the overall market size and presents forecast till 2016, a key focus of the report is the increasing role of biopharmaceutical products. The growing interest in biotechnology development has led to the metamorphosis of the pharmaceutical industry, resulting in the subset industry of biopharmaceuticals. The big players in the pharma industry, including Pfizer, Merck, and Novartis, have been the first few to reap the benefits of investing in biotechnology through both organic as well as inorganic growth mechanisms.
Market forecasts include the biopharmaceuticals currently in the market as well as those projected to enter the market by the end of the forecast period in 2016. Market challenges, drivers, and restraints have also been identified and assessed. Selected late stage pipeline analysis is also included.
This report analyzes the biopharmaceutical industry’s products, features, companies, market size and potential, and patent portfolios. The impact of the Medicare and Medicaid policies and individual plan behaviors on the biopharmaceutical industry is also discussed.
The briefing will cover an analysis of trends and current focus of the U.S. biopharmaceutical market and the challenges faced by the industry. The impact of biopharmaceuticals on the U.S. healthcare market will also be discussed during the briefing.
MarketsandMarkets (M&M) is a global market research and consulting company based in the U.S. We publish strategic advisory reports and serve as a business intelligence partner to Fortune 500 companies across the world. MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services.
M&M Banking and Financial Services practice recognizes the challenges that financial institutions face bringing the right products to market. Our reports and consulting practice provide a unique perspective allowing the financial institution to see and experience the best way to achieve their product goals. Through a mix of case studies, primary research, and business modeling we provide a 360° view to identify how you can create, capture, and keep the value of your product and out think the competition.
Note: An email containing the Login Details and Time of the Analyst Briefing will be sent to you soon after your successful registration.